Rapid emergence of transmissible SARS-CoV-2 variants in mild community cases

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

PROTECT COVID-19 National Core Study Genotype-to-Phenotype UK National Virology Consortium (G2P-UK) NIHR (NIHR200927) Department of Health and Social Care COVID-19 Fighting Fund award NIHR Health Protection Research Units (HPRUs) in respiratory infections and in modelling and health economics

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by the Health Research Authority (Research Ethics Committee reference 20/NW/0231) and samples were obtained with written informed consent.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes